A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab
- Colorectal Cancer (CRC)
The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.
The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.
The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.
A Multicenter Non-Interventional Study Exploring the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With a Chemotherapy Combined With Bevacizumab
- Patients treated in first line with bevacizumab for whom it is decided, and who are clinically considered eligible, to continue the treatment with bevacizumab beyond PD1.
- Women of childbearing potential have to use effective contraception during (and up to 6 months after) treatment.
- Availability of specific retrospective data at diagnosis and during 1st line treatment
- Patients who are participating or participated in first line in any other interventional clinical trial involving non-standard of care procedures impacting the body composition
- Dementia or another mental condition making it impossible to fill out questionnaires
For the latest version of this information please go to www.forpatients.roche.com